Biohaven has successfully tested vashepant, a new anti-migraine drug. It is the first CGRP inhibitor in the form of an intranasal spray. According to Remediium, there are now several injectable forms of CGRP inhibitors on the market designed to reduce the incidence of migraine attacks. But applying the spray will be easier and more convenient than injecting.

Studies have shown that high doses of the drug (10 and 20 milligrams) provided a 22.5% reduction in pain intensity within two hours after administration. The severity of hypersensitivity to sounds, light and nausea decreased by 41.9-42.5%. The effect lasted a long time - for 48 hours, repeated administration of the drug was not required. Importantly, therapy was well tolerated by patients, and side effects were mild in 80% of cases. The spray, according to the developers, is absolutely safe for the liver.